28-Mar-2024
No headlines found.
PRNewswire (Thu, 7-Mar 9:00 PM ET)
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System
Globe Newswire (Tue, 5-Mar 9:00 AM ET)
Globe Newswire (Wed, 28-Feb 4:05 PM ET)
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Globe Newswire (Wed, 7-Feb 4:30 PM ET)
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.
Silk Road Medical trades on the NASDAQ stock market under the symbol SILK.
As of March 28, 2024, SILK stock price declined to $18.32 with 950,657 million shares trading.
SILK has a beta of 2.01, meaning it tends to be more sensitive to market movements. SILK has a correlation of 0.06 to the broad based SPY ETF.
SILK has a market cap of $713.48 million. This is considered a Small Cap stock.
Last quarter Silk Road Medical reported $47 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.09.
In the last 3 years, SILK stock traded as high as $67.49 and as low as $6.08.
The top ETF exchange traded funds that SILK belongs to (by Net Assets): VTI, IWM, VXF, VB, IWO.
SILK stock has underperformed the market in the last year with a return of -52.6%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SILK shares. However, SILK has outperformed the market in the last 3 month and 2 week periods, returning +49.2% and +18.3%, while SPY returned +10.1% and +1.7%, respectively. This indicates SILK has been having a stronger performance recently.
SILK support price is $17.92 and resistance is $19.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SILK stock will trade within this expected range on the day.